Ocera Therapeutics (OCRX) Reports Q4 Loss of $0.22/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ocera Therapeutics (OCRX) Up 16% in Pre-Market Trading; Gained 83% Yesterday Post OCR-022 Positive Data Announcement
March 9, 2017 8:35 AM ESTOcera Therapeutics (NASDAQ: OCRX) shares are trading positive again in the pre-market session up 16%, adding to the 83% move from yesterday's session following news of positive OCR-022 data.
... MoreOcera Therapeutics (OCRX) Sees 85%+ Gain on 45x Normal Volume Following Positive OCR-002 Data
March 8, 2017 11:44 AM ESTOcera Therapeutics (OCRX) shares in focus, seeing 85%+ gains in today's session on 45-times the normal volume rate, after the company reported positive OCR-002 data results this morning, citing lower ammonia, correlated statistically with clinical improvement in patients with Hepatic Encephalopathy.
... MoreOcera Therapeutics (OCRX) Says Data Confirms OCR-002 Lowered Ammonia, Correlated Statistically with Clinical Improvement in Patients with HE
March 8, 2017 8:07 AM EST(Updated - March 8, 2017 8:13 AM EST)
(Update modifies wording in headline)
Ocera Therapeutics, Inc. (NASDAQ: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced it will report additional encouraging results from its Phase 2b STOP-HE study of intravenous (IV) OCR-002 in hospitalized patients with Hepatic Encephalopathy (HE) at the Cowen and Company 37th Annual Healthcare Conference at 11:20 AM Eastern Time today.
"Further analysis of the data from our STOP-HE trial confirms that OCR-002 rapidly and safely lowered ammonia and, importantly, the ammonia reduction correlated... More
Ocera Therapeutics (OCRX) Halted, News Pending
March 8, 2017 7:59 AM ESTOcera Therapeutics (NASDAQ: OCRX) Halted, News Pending
... More